<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04533581</url>
  </required_header>
  <id_info>
    <org_study_id>ME-401-K02</org_study_id>
    <nct_id>NCT04533581</nct_id>
  </id_info>
  <brief_title>Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)</brief_title>
  <official_title>A Japanese Phase 2 Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Kirin Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Kirin Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of ME-401&#xD;
      in the treatment of Japanese participants with Relapsed or Refractory indolent B-Cell&#xD;
      Non-Hodgkin's Lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2020</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>ORR is measured as the proportion of subjects achieving the best response rating of complete response (CR) or partial response (PR) prior to first progressive disease (PD).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of ME-401 as assessed by the duration of response (DOR)</measure>
    <time_frame>Up to approximately 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of ME-401 as assessed by the progression-free survival (PFS)</measure>
    <time_frame>Up to approximately 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of ME-401 as assessed by CR</measure>
    <time_frame>Up to approximately 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of ME-401 as assessed by the Time to treatment failure (TTF)</measure>
    <time_frame>Up to approximately 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of ME-401 as assessed by the objective response rate (ORR)</measure>
    <time_frame>Up to approximately 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of ME-401 as assessed by the number of participants with treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Up to approximately 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of ME-401 as assessed by the time to occurrence of adverse event of special interest (AESI)</measure>
    <time_frame>Up to approximately 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration level of ME-401</measure>
    <time_frame>Up to approximately 4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Indolent B-cell Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>ME-401</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ME-401</intervention_name>
    <description>In the first 2 cycles (1 cycle is 28 days), subjects will be administered 60 mg of ME-401 orally once a day on a continuous schedule (CS). After that, subjects will be administered 60 mg of ME-401 orally once a day for the first 7 days, followed by rest for 21 days on an intermittent schedule (IS).</description>
    <arm_group_label>ME-401</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 20 years or older at the submission of the written informed consent form&#xD;
&#xD;
          -  Patients that have undergone therapy after at least 2 prior systemic therapies&#xD;
             (anti-CD20 Ab, chemo, and so on) for relapsed or refractory B-cell NHL&#xD;
&#xD;
          -  Patients who have not undergone phosphatidylinositol 3-kinase (PI3K) inhibitors to&#xD;
             date&#xD;
&#xD;
          -  Patients who have not undergone Bruton's tyrosine kinase (BTK) inhibitors to date&#xD;
&#xD;
          -  Patients with Eastern Cooperative Oncology Group Performance status (ECOG PS) &quot;0 or 1&quot;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with relapsed or refractory B-cell NHL who is categorized into Small&#xD;
             lymphocytic lymphoma (SLL), Waldenstr√∂m's macroglobulinemia (WM), Lymphoplasmacytic&#xD;
             lymphoma (LPL) by WHO classification&#xD;
&#xD;
          -  Patients who have been histologically confirmed FL Grade 3b transformation from&#xD;
             Follicular lymphoma (FL) to an aggressive lymphoma at least once&#xD;
&#xD;
          -  Patients with lymphomatous involvement of the central nervous system&#xD;
&#xD;
          -  Patients with uncontrolled clinically significant illness&#xD;
&#xD;
          -  Patients with active interstitial lung disease or a history thereof&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kyowa Kirin Co., Ltd.</last_name>
    <phone>+81-90-9975-7702</phone>
    <email>clinical.info.jp@kyowakirin.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hokkaido University Hospital of the National University corporation</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 26, 2020</study_first_submitted>
  <study_first_submitted_qc>August 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2020</study_first_posted>
  <last_update_submitted>October 2, 2020</last_update_submitted>
  <last_update_submitted_qc>October 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

